Alpha-1 antitrypsin deficiency  by Kelly, Emer et al.
Respiratory Medicine (2010) 104, 763e772ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedREVIEW
Alpha-1 antitrypsin deficiencyEmer Kelly*, Catherine M. Greene, Tomas P. Carroll, Noel G. McElvaney,
Shane J. O’NeillDepartment of Respiratory Research, Royal College of Surgeons in Ireland, Beaumont Hospital, Education Research
Building, Beaumont Road, Dublin, Ireland
Received 19 June 2009; accepted 24 January 2010
Available online 20 March 2010KEYWORDS
Alpha-1 antitrypsin;
Alpha-1 antitryspin
deficiency;
Chronic obstructive
pulmonary disease
(COPD);
SERPINA1 gene* Corresponding author.
E-mail address: emerkelly@rcsi.ie
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.01.016Summary
Objective: To review the topic of alpha-1 antitrypsin (AAT) deficiency.
Method: Narrative literature review.
Results: Much work has been carried out on this condition with many questions being answered
but still further questions remain.
Discussion and conclusions: AAT deficiency is an autosomal co-dominantly inherited disease
which affects the lungs and liver predominantly. The clinical manifestations, prevalence,
genetics, molecular pathophysiology, screening and treatment recommendations are sum-
marised in this review.
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AAT deficiency is a genetic disorder that affects an
approximated 3.4 million individuals worldwide, when
individuals with the ZZ, SZ or SS phenotype are included.1
This condition is clinically characterised by early-onset
emphysema and liver disease.
AAT deficiency was first documented by Laurell and
Eriksson in 1963.2 They carried out a painstaking review of
1500 serum protein electrophoresis gels in which the band
for the a1 was absent. Three out of five of these patients
developed emphysema at a young age. Since that time
much work has been done on AAT deficiency elucidating the
genotypes and the phenotypes of the condition, the clinical
variation in symptoms and signs, the method of diagnosis
and of screening and the possibilities for treatment. Many
questions have been answered but with these many more
questions surface.
Prevalence of AAT deficiency
AAT deficiency is a genetic cause of Chronic Obstructive
Pulmonary Disease (COPD). The frequency of AAT deficiency
can only be estimated. In one study of 965 patients with
COPD who were screened for AAT deficiency 1.9% were
shown to have the disease.3 Extrapolating from the National
Health Information Survey in the USA which estimates that
3.1 million Americans have emphysema this would suggest
that in 59,000 of these patients the emphysema is caused by
AAT deficiency. Under-recognition of AAT deficiency is
a problem. When given a questionnaire addressing the
number of doctors seen for symptoms attributable to AAT
deficiency and the onset of AAT deficiency-related symp-
toms the 300 patients studied reported a mean delay
between the first symptom and the initial diagnosis of the
disorder of 7.2 years.4 The delay in an initial diagnosis was
shown in this study to be associated with adverse outcomes
for the patients in relation to psychosocial effects. Other
consequences include slowed opportunities to offer specific
counselling and therapy. More recently this delay has
decreased slightly to a mean of 5.6 years5 demonstrating
still further room for improvement.
Clinical manifestations
The clinical disease associated with AAT deficiency can
present in a number of ways but the most frequent organs
affected are the lungs and the liver. In the lung, emphy-
sema is the most common manifestation. The emphysema
associated with AAT deficiency tends to be early in onset
(i.e., in the fourth and fifth decades), panacinar inpathology and disproportionate in its effect on the lung
bases (compared to the more apical distribution in AAT
replete patients).6e8 Evidence for the association of bron-
chiectasis with AAT deficiency is mixed. Larsson originally
noted bronchiectasis in 11.3% of 246 patients with the ZZ
phenotype.9 The NHLBI registry reported bronchiectasis in
only 2% of 1129 participants10 and in a case-control study.
Cuvelier and colleagues recorded no excess frequency of
AAT deficiency in patients with bronchiectasis compared
with those without bronchiectasis.11 A more recent study
characterising the computed tomographic phenotype of
patients with AAT deficiency found that clinically significant
bronchiectasis occurred in 27% of the patients studied,
greater than previously recognised.12
After the lung the liver is the next most commonly
affected organ in AAT deficiency. In a Swedish population-
based screening study of 200,000 neonates, 22 (18%) of 120
babies with the Z allele had evidence of some liver
dysfunction over follow-up to the age of 6 months,
including obstructive jaundice (12%) and minor abnormali-
ties (7%).13 When liver dysfunction is present the risk of
progressing to liver cirrhosis was estimated to be 50%; 25%
died within the first decade of life and 2% developed
cirrhosis later in childhood.14 Larsson’s study followed 246
patients with the Z mutation for up to 11 years and found
liver disease in 12.2% (cirrhosis in 11.8%, neonatal hepatitis
in 0.4%, and hepatoma in 3.3%).9 Finally Eriksson’s analysis
of 38 post-mortem examinations from among 58 decedents
with expected AAT deficiency in Malmo, Sweden observed
cirrhosis in 34% (n Z 14), in whom cirrhosis was suspected
during life in 64%.15 The established association of Z
mutation AAT deficiency with liver disease has lead to the
recommendation for screening all neonates, children and
adults with an unexplained liver disease for this condi-
tion.16 Low AAT levels can lead to a diagnosis of AAT defi-
ciency, but there is no correlation between AAT level and
risk of liver disease. The risk of cirrhosis in SZ patients is
now established. The S variant is known to have an
increased susceptibility to polymerisation, although this is
marginal compared with the more conformationally
unstable Z variant.17 There has been speculation that the
two may interact to produce cirrhosis, but this has never
been demonstrated experimentally.
Panniculitis is a skin condition associated with AAT
deficiency. This condition however is not frequent with an
occurrence of about 1 in 1000 patients with AAT
deficiency.18
Vasculitis is another of the less frequently occurring
diseases associated with AAT deficiency. An over-
representation of abnormal AAT phenotypes in people
with antiproteinase 3 antibody-positive (i.e., c-ANCA-posi-
tive) vasculitis in case series has established an association
Figure 1 Diagnostic AAT isoelectric focussing gel. A sebla 18
AAT isoelectro focussing gel showing migration of four different
AAT isoformsdMM, MZ, MS and ZZ.
Table 1 PI Phenotypes and the likely clinical
consequences.
Phenotype Serum concentration
of AAT
COPD risk
Pi-MM 20e53 mmol/L General population
Pi-MS 20e48 mmol/L Very low/general
population
Pi-SS 15e33 mmol/L Low
Pi-MZ 12e35 mmol/L Low
Pi-SZ 8e19 mmol/L Variable
Pi-ZZ 2.5e7 mmol/L High
Pi-Z-null <2.5 mmol/L Very high
Pi-null-null None Very high
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Z allele among c-ANCA-positive individuals was 5.6e17.6%,
which exceeds by three-fold to nine-fold the prevalence in
healthy people.16,19 The ATS/ERS statement also recom-
mends testing for all adults with c-ANCA-positive vasculitis.
The precise risk of developing emphysema in people
with the ZZ phenotype is not known. Tobin et al. assessed
the risk of developing emphysema in ZZ siblings of index
cases.20 They found that emphysema was present radio-
graphically in 90% of smokers compared with 65% of non-
smokers. A Swedish study found that in adults homozy-
gous for the Z allele only 29% of never smokers and 10% of
ever smokers were healthy.21 The remainder had lung
disease. Findings from post-mortems reported in the same
study and of CT studies reported by Parr et al. suggest that
only 14e20% of Z homozygotes were free of COPD.22 The
most common cause of death in patients with AAT defi-
ciency is respiratory failure (accounting for 50e72% of
deaths) followed by liver cirrhosis (10e13%).23,24 The
observed overall yearly mortality rate ranges from 1.7% to
3.5%.9,23e26 Factors found to be associated with increased
mortality include older age, lower education, lower FEV1
predicted, lung transplant, and not receiving augmentation
therapy.23 In another study only age and CT assessment of
proportion of emphysema predicted respiratory and all-
cause mortality.24
There is also an association of the Z allele of AAT with
asthma,27,28 pancreatitis29 and vascular aneurysms.30,31
Associations with some neuropsychological conditions
have also been suggested. AAT S or Z polymorphisms were
shown to be present in 25% of persons with anxiety disorder
and 42% of persons with bipolar disorder compared to 10%
of a control group without pre-existing affective disorder.32
A recent study comments on how low serum AAT in family
members of individuals with autism correlates with PiMZ
genotype33 and another study suggests a link between the Z
allele and ‘‘intense creative energy’’.34
Genetics
AAT deficiency is an autosomal co-dominant condition. The
AAT protein is encoded by the SERPINA1 gene, previously
known as the protease inhibitor (PI) gene, the locus for
which is located on chromosome 14q32.1.35e39 This gene for
AAT has been cloned and sequenced.40,41 The SERPINA1
gene is 12.2 kb in length with seven exons and six introns.
The SERPINA1 gene or the PI locus is highly polymorphic
with approximately 123 single nucleotide polymorphisms
(SNPs) listed.42 Differences in speed of migration of
different protein variants on gel electrophoresis have been
used to identify the PI phenotype, and these differences in
migration relate to variations in protein charge resulting
from amino acid alterations (Fig. 1).43 The M allele results
in a protein with a medium rate of migration; the Z form of
the protein has the slowest rate of migration. Some indi-
viduals inherit null alleles that result in protein levels that
are not detectable. Individuals with a Z pattern on serum
isoelectric focusing are referred to as phenotype PIZ
(encompassing both PIZZ and PIZnull genotype variants).
The S variant occurs at a frequency of 0.02e0.03 and is
associated with mild reductions in serum AAT levels. The Z
variant is associated with a severe reduction in serum AATlevels. The most common alleles are the M variants with
allele frequencies of greater than 0.95 and normal AAT
levels (Table 1).
The Z allele (Glu342Lys) causes the most severe plasma
deficiency and is most prevalent in southern Scandinavia
and the northwest European seaboard, with gene
frequencies reducing toward the south and east of the
continent.44,45 In contrast, the S allele (Glu264Val) causes
only mild plasma deficiency and is most common in
southern Europe and becomes less frequent as one moves
northeast. The frequencies of the Z allele in the United
States are similar to the lowest frequencies in Europe, but
the S allele is more common than in northern Europeans.
AAT deficiency is infrequent in the Asian, African and the
Middle Eastern populations.1
Even in patients with severe AAT deficiency, the devel-
opment, manifestations and progression of COPD are highly
variable, which suggest that modifier genes, environmental
exposures, and the combined effect of gene and environ-
mental factors may be relevant to disease expression. The
altered AAT protein is the product of a single gene, but the
disease phenotype is probably a result of many genes.
Genetic modifiers of lung disease in AAT-deficient
766 E. Kelly et al.individuals may also provide insight into COPD unrelated to
AAT deficiency.
The AAT protein, that the SERPINA1 gene gives rise to, is
52 kDa and includes 394 amino acids with the active site of
the enzyme inhibitor at methionine 358. It is an anti-
protease. Initially labelled ‘‘antitrypsin’’ was later found to
have a much higher affinity for the protease neutrophil
elastase (NE). In its activity inhibiting NE, AAT plays
a pivotal role in the delicate proteaseeantiprotease
balance.
The molecular defect in the Z allele is a substitution of
a lysine for a glutamic acid at position 342 due to a single
base alteration in the gene. The low protein levels result
from polymerisation of the protein within the hepatocyte
endoplasmic reticulum, with subsequent reduction in
serum levels due to intracellular accumulation.46 In ZZ
homozygous patients the plasma AAT level is 10% of the
normal M allele and 60% in the MZ heterozygote (50% from
the M allele and 10% from the Z allele).
Molecular pathophysiology
The AAT molecule is an acute phase glycoprotein.47 This is
synthesised and secreted mainly in the liver by hepato-
cytes48,49 but also synthesised by and secreted from
macrophages,50 intestinal51 and bronchial epithelial cells.52
It not only inhibits pancreatic trypsin53 but also inhibits
many other proteinases including neutrophil elastase,
cathepsin G54 and proteinase 3.55
Crystal structures have shown that AAT is composed of
three b sheets (AeC) and an exposed mobile reactive loop
that presents a peptide sequence as a pseudosubstrate for
the target proteinase.56e61 The critical amino acids within
this loop are the PIePI0 residues, methionine serine, as
these act as ‘‘bait’’ for neutrophil elastase.62 After dock-
ing, the enzyme cleaves the P1eP10 peptide bond of AAT
and the proteinase is inactivated by a mousetrap action
that swings it from the upper to the lower pole of the
protein in association with the insertion of the reactive loop
as an extra strand in b-sheet A.63e68 This altered product of
the AAT bound to its substrate is recognised by hepatic
receptors and cleared from circulation.69 The conforma-
tional change that underlies the clinical disease of AAT
deficiency interferes with the processing of this altered
protein in the hepatocyte (Fig. 2).
Molecular pathology of the liver disease
Current evidence tells us that the liver disease in Z-variant
AAT deficiency is caused by an accumulation of the
abnormal protein in the liver rather than a plasma defi-
ciency. Strong support is provided by the fact that null
alleles, which produce no AAT, are not associated with
cirrhosis.70 In addition to this, over expression of ZAAT in
animal models results in liver damage.71,72
The presence of the Z mutation causes a conformational
change in the AAT molecule. The b sheet A opens leaving it
susceptible to interaction with another AAT molecule to
form a dimer or following interaction with further AAT
molecules to form a polymer.57,73e75 These polymers get
trapped in the endoplasmic reticulum. The experimentalproof of this was in work from Lomas et al. showing polymer
formation when the purified plasma ZAAT is incubated
under physiological conditions.74 These polymers were also
found in inclusion bodies in the liver of a Z heterozygotic
patient74,76 and in hepatic cell lines expressing the Z
variant.77 In work on Xenopus oocyte cells, blocking the
polymerisation with point mutations was shown to increase
secretion of mutants of AAT.78 The Z mutation causes most
of the unstable protein to form polymers.
The method by which the hepatocytes deal with the
polymers has been the source of much study. Trimming
asparagine linked oligosaccharides target ZAAT polymers
into an efficient non-proteosomal disposal pathway.79e81
The proteosome pathway has been shown to be important
in some hepatic82 and extrahepatic mammalian cell
lines.83,84 Retained ZAAT stimulates an autophagic response
in the hepatocyte.85,86
The endoplasmic reticulum has a very important role in
protein folding and the handling of misfolded proteins.
Specific signaling pathways87 and effector mechanism have
evolved to deal with the temporal and developmental
variation in the ER load. The upstream signal that activates
these pathways is referred to as ER stress and is defined
functionally as an imbalance between the load of proteins
facing the ER and the organelle’s ability to process that
load. The cellular response to ER stress has four main
functional components: ER overload response (EOR), the
unfolded protein response (UPR),88 a decrease in protein
synthesis, and programmed cell death.89
There is a great heterogeneity of liver disease in ZAAT
patients. Experimental work shows effects with an increase
in temperature, concentration of the substrates for poly-
merisation73,74 and genetic factors.90,91 Results regarding
temperature vary in different studies. One study shows no
increase in intracellular ZAAT in response to raised
temperatures92 but further work in a Drosophila model of
AAT deficiency show a clear temperature dependence of
polymerisation in vivo.93
Cigarette smoking is the most important factor in the
development of the lung disease associated with AAT defi-
ciency.94,95 It is in the lung that the imbalance in the pro-
teaseeantiprotease balance is seen to have a major effect.
In the case of Z-variant AAT deficiency there is less AAT in
the lung.96 The AAT that is present is 5 times less effective
than normal AAT.97e100 The residual AAT is susceptible to
inactivation by oxidation of the P1 methionine residue by
free radicals from leukocytes or direct oxidation by ciga-
rette smoke.54,101e103 The Z AAT also favours the formation
of polymers in the lung.104 ZAAT-deficient patients have
excess neutrophils in lavage fluid105 and in tissue sections of
the lung106 possibly related to the chemoattractant
effect of an excess of leukotriene B4 (LTB4) and interleukin
(IL)-8107,108 and the polymers themselves.109 These
circumstances of unopposed proteolytic enzyme activity
and an increase in inflammatory conditions cause the
trademark emphysema of this disease.
Screening
Recommendations for screening for AAT deficiency have
been clarified with publication of the American Thoracic
Society/European Respiratory Society statement on
Liver: ZAAT accumulation in 
hepatocyte ER leading to liver disease 
Circulation: Decreased AAT in 
circulation 
Lung: Decreased AAT in lung 
leading to unopposed protease 
activity
Figure 2 In Z-variant AAT deficiency accumulation of the abnormal protein in the endoplamic reticula of hepatocytes leads to
the liver disease of AATD. Decreased AAT enter circulation and arise in the lung leading to decrease in the antiprotease activity in
the lung due to a lower and a higher amount of inactive AAT. This leads to increased protease activity and the destructive process
which leads to emphysema.
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main benefits of early detection of AAT deficiency are 1.
smoking prevention/cessation 2. minimizing the hazards of
occupational respiratory pollutants 3. allowing opportuni-
ties to receive augmentation therapy and 4. the potential
for family planning and guided genetic counselling/
testing.110 Symptomatic individuals may require life-long
therapy, and early detection may reduce the clinical and
economic burdens of progressive lung deterioration.111
Smoking cessation advice has proven to be effective in
patients with AAT deficiency. Follow-up of the original
patients from the 1970s AAT deficiency screening program
in Sweden who are now 30 years of age has shown that
smoking is less common in them than in control subjects.112
Further studies showed that following screening the
subsequent provision of information and advice prevented
the majority of affected adolescents from smoking.113,114
It is perceived that knowledge of AATD diagnosis should
aid affected individuals in their occupational choices,
allowing them to avoid exposure to environmental agents
(e.g. avoiding careers in steel-manufacturing).
Augmentation therapy is available and will be discussed
in more detail in the next section. Early diagnosis with
screening programs allows this to be instigated while lung
function is preserved.
The impact of diagnosis through screening has multiple
implications for the individual. There is a psychological
impact of the diagnosis which can be positive for patients
satisfied to have found a reason for their symptoms but may
be negative with concerns for the future. The ethics of
screening family members raises a challenge especially in
respect to minors who have the decision made for them.
The consequences of a confirmed diagnosis of AATD include
possible discrimination for example by employers and
insurers.
Screening with genotyping is recommended. AAT levels
may be less expensive but establishing the genotype givesmore information about the likelihood of developing clin-
ical consequences of the disease.Treatment of AAT deficiency
As AAT deficiency results in COPD the medical therapy for
COPD also applies to AAT deficiency. These have been
outlined in previous published guidelines of the ATS, BTS
and the GOLD guidelines.115e117 Most patients with AAT
deficiency and obstructive lung disease find symptomatic
benefit from bronchodilators even though objective bron-
chodilator responsiveness may be lacking. Those with
proven bronchial hyperreactivity may be given an inhaled
steroid with the presumption that a decrease in bronchial
inflammation may reduce the loss in FEV1 over time.
A study has suggested benefit of inhaled steroids in some
patients with AAT deficiency-related lung disease, although
it is not clear which patients benefit.118 Antibiotics are
recommended for treatment of exacerbations triggered by
bacterial infections. Portable oxygen is recommended for
those who desaturate with exercise but otherwise long-
term oxygen therapy is only recommended for those with
severe hypoxaemia. This should be prescribed in concor-
dance with the ATS and ERS criteria.115,116 Oral steroids can
be cautiously considered in patients with a clear asthmatic
component to their disease and long-term use should be
avoided. Co-morbidities that accompany COPD outside the
setting of AAT deficiency should always be borne in mind.
These include depression, anxiety and malnutrition.
Pulmonary rehabilitation can offer benefit; improving
endurance, reducing dyspnoea and reducing number of
hospitalisations.119
Treatment specific to AAT deficiency is centred on AAT
augmentation therapy. There are four potential treatment
options (1) intravenous human plasma-derived augmenta-
tion therapy, (2) augmentation therapy by inhalation, (3)
768 E. Kelly et al.recombinant AAT augmentation therapy, and (4) synthetic
elastase inhibition.
Intravenous human plasma-derived augmentation
therapy
Since the early 1980s intravenous administration of purified
human AAT concentrate was shown to increase lung levels
of AAT in AAT-deficient patients.96,120 Patients receiving
once weekly IV doses increased the antineutrophil elastase
capacity in lung epithelium lining fluid by 60e70%. A puri-
fied preparation was manufactured and shown to be bio-
logically active121e123 and this lead to the US Food and Drug
Administration approval in the United States in 1988.
Randomised placebo-controlled trials evaluating the effect
of IV AAT replacement therapy in attenuating the devel-
opment of emphysema are lacking with only one pub-
lished.124 Recommendations on the use of augmentation
therapy are based on the ATS/ERS guidelines.16
Decline in FEV1 has been shown to be lower in patients
treated with IV augmentation therapy compared with
untreated patients.125,126 In comparing the different
degrees of functional impairment, a significant effect of
the treatment was demonstrated only in the group of
patients with an initial FEV1 of 31e65% predicted. This non-
randomised study showed that weekly infusion of human
AAT in patients with moderately reduced lung function may
slow the annual decline in FEV1. In a similar study from the
NHLBI Registry the mortality rate was lower in those
receiving augmentation therapy as compared with those
not receiving therapy and mean FEV1 decline was only
slowed in the subgroup of patients with moderate emphy-
sema. The only randomised trial was small with only 58
patients. The number of patients limited the only signifi-
cant finding to being an attenuation in the loss of lung
density in the treated group.124
Augmentation therapy by inhalation
Aerosol application of AAT in patients with AAT deficiency
increases AAT concentration and anti-elastase activity in
the lower respiratory tract in a dose-dependent fashion.127
Preliminary data suggest that one or twice daily adminis-
tration of aerosolized AAT may produce sustained anti-
elastase protection of the lungs.
Recombinant AAT augmentation therapy and
synthetic elastase inhibition
A number of recombinant forms of AAT have been devel-
oped as well as recombinant secretory leukoprotease
inhibitor128 and several synthetic low molecular weight
elastase inhibitors are being evaluated but their clinical
efficacy and safety have not been reported.
In summary the available studies indicate a lowered
overall mortality and a slower rate of FEV1 decline in
augmentation therapy recipients with FEV1 values of 35e
65% of predicted.
Lung transplantation may be recommended for some
patients with end-stage lung disease. Due to limitations on
available donor lungs single lung transplant is morecommon despite the fact that outcome has been shown to
be better in patient who receive double lung transplant.
Approximately 12% of all lung transplant operations for
emphysema are due to AAT deficiency.129 Five year survival
rates following lung transplant is approximately 50% with
bronchiolitis obliterans being the major cause of death
post-transplant.130
Lung volume reduction surgery
Lung volume reduction surgery (LVRS) improves exercise
capacity and relieves dyspnoea in patients with usual
emphysema but the story is less clear in AAT deficiency.
One study showed a benefit to bilateral LVRS in AAT-defi-
cient patients with emphysema but functional measure-
ments (except 6 min walk test) returned to baseline at 6e
12 months.131 LVRS was not recommended in the ATS/ERS
guidelines for management of AAT deficiency in their 2003
statement.
Future research
A large volume of research continues in the field of AAT
deficiency. Three examples are in the field of candidate
modifier genes, anti-inflammatory proteins and potential
synthetic antiproteases.
Although the gene responsible for the conformational
change in AAT has been identified variations in the
presentation of patients strongly suggests the role for
candidate modifier genes. An example of a potential
modifier is Selenoprotein S/SEPS1. This selenoprotein has
been shown to decrease manifestations of ER stress in an in
vitro model of Z-variant AAT deficiency.132
Other anti-inflammatory therapies will continue to be
investigated in this disease. Recent work showed that bron-
choalveolar lavage (BAL) fluid from patients with AAT defi-
ciency containing free neutrophil elastase had increased
cathepsin B and matrix metalloproteinase-2 (MMP2) activi-
ties compared with BAL fluid from healthy volunteers. AAT
augmentation therapy to AAT-deficient individuals reduced
cathepsin B and MMP-2 activity in BAL fluid in vivo. Further-
more, AAT-deficient patients had higher levels of secretory
leukocytepeptidase inhibitor (SLPI) and lactoferrin after AAT
augmentation therapy suggesting a novel role for AAT inhi-
bition of NE-induced upregulation of MMP and cathepsin
expression both in vitro and in vivo.133
Conclusion
AAT deficiency is an under diagnosed disease causing much
morbidity and mortality in those affected. Much has been
elucidated about the genetics and the molecular patho-
physiology and potential therapies of this condition. Further
research continues to investigate the varying presentations
between different patients with AAT deficiency and the full
effect of AAT and the body’s response to it.
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